Home >> About

News & Events

Dr Magid Abou-Gharbia, Associate Dean for Research, Professor & Director, Moulder Center for Drug Discovery Research, School of Pharmacy, Temple University and formerly Senior VP of Wyeth, Head of Chemical & Screening Processes, will chair a roundtable panel discussion at the ChemSpec India 2013 Meeting.

Panel discussions on supplying services to the drug industry at Chemspec conferences this summer featured executives from companies one would expect to find on such panels. The chief executives of contract service firms and outsourcing managers at top drug companies discussed changes in science and business that are creating opportunities in contract R&D and manufacturing.

A more surprising participant on these panels was the moderator: Magid Abou-Gharbia, director of the Moulder Center for Drug Discovery Research at Temple University’s School of Pharmacy. Still best known in the industry as the former head of chemical and screening sciences at Wyeth, Abou-Gharbia now directs an up-and-comer in the field of academic drug discovery. At the center, he is a proponent for expanding a facet of scientific research that was once anathema in academia: the business model.

Compared to the recent rocky roads of other U.S. industries — such as the automotive industry—the field of prescription drugs might appear to be holding its own: The IMS Institute for Healthcare Informatics reported its total 2010 sales to be more than $307 billion.

What that number does not reveal is that big pharma suffers from an “innovation gap,” the amount of products—or rather, lack thereof— coming through the industry pipeline.  In 1996, the industry hit its peak, with 56 new drugs approved for consumer use by the U.S. Food and Drug Administration. Since then, new drug approvals have steadily declined to as few as 18 per year.

Gothenburg, Sweden – 17 April 2012: Cortendo today announced an update and further information for the discovery collaboration in the cortisol modulation area with the Moulder Center for Drug Discovery Research at Temple University. The goal of the collaboration is to discover next generation compounds for type 2 diabetes and metabolic syndrome as well as orphan drug diseases.

Rochester, NY April 9, 2012: A new program, jointly funded by the University of Rochester Medical Center (URMC) and the Moulder Center for Drug Discovery Research at Temple University, will help researchers identify and test chemical compounds that could be candidates for new drugs.

The $500,000 fund, called the Drug Discovery Pilot Award Program, represents the next stage in a complementary relationship that was formed between URMC and the Moulder Center last year.

PHILADELPHIA – (February 22, 2012) – The Wistar Institute and The Moulder Center for Drug Discovery Research at Temple University today announce their new partnership to accelerate the transition of biomedical research into new drug therapies for cancer and other diseases.

The American Association of Colleges of Pharmacy (AACP) today announced the recipients of the 2011-2012 New Investigator Awards (NIA). The Awards support new faculty research in multidisciplinary areas such as biological sciences, chemistry, pharmaceutical sciences, pharmacy practice, and social and administrative sciences. This year’s 18 Award recipients are investigating topics as diverse as medication self-management, treatment for cocaine addiction and withdrawal, and the impact of Medicare payment cuts on treatment choices and patient outcomes.

Compared to the recent rocky roads of other U.S. industries — such as the automotive industry—the field of prescription drugs might appear to be holding its own: The IMS Institute forHealthcare Informatics reported its total 2010 sales to be more than $307 billion.

What that number does not reveal is that big pharma suffers from an “innovation gap,” the amount of products—or rather, lack thereof— coming through the industry pipeline.  In 1996, the industry hit its peak, with 56 new drugs approved for consumer use by the U.S. Food and Drug Administration. Since then, new drug approvals have steadily declined to as few as 18 per year.

11/28/2011 - GVK Biosciences (GVK BIO), Asia’s leading drug discovery research & development organization, announced today that it has entered into a drug discovery alliance with the Moulder Center for Drug Discovery Research at Temple University.

As part of the multi-year integrated drug discovery collaboration, GVK BIO will be responsible for the target validation, lead identification and lead optimization of small molecules in selected therapeutic areas, including cardiovascular, metabolic, and central nervous system disorders.

Philadelphia, PA (11/15/2011) - Dr Magid Abou-Gharbia will be bringing the insights from a distinguished career to a key panel discussion at Chemspec USA. We caught up with him at Temple University in Philadelphia

Like so many people in the US chemicals industry, Dr Magid Abou-Gharbia, director of the Moulder Center for Drug Discovery within the School of Pharmacy at Temple University in Philadelphia, knew Ben Jones during his time at the American Chemical Society (ACS). He frequently participated in ACS conferences, notably on one his favourite topics, the future of the 'chemical enterprise' as it relates to the pharmaceuticals industry.

Pages

Temple University
Moulder Center for Drug Discovery Research

Temple University School of Pharmacy
3307 N Broad Street
Philadelphia, PA 19140